{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
INN:zorevunersen [INN]
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT01743807: Phase 1 Interventional Terminated Relapsed Acute Lymphoblastic Leukemia
(2012)
Source URL:
Class:
NUCLEIC ACID
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00002403: Phase 1 Interventional Completed HIV Infections
Source URL:
Class:
NUCLEIC ACID
Status:
Designated
Source:
EU-Orphan Drug:EU/3/19/2171
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2024)
Source:
NDA217424
(2024)
Source URL:
First approved in 2024
Source:
NDA217424
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(2016)
Source:
NDA208114
(2016)
Source URL:
First approved in 2016
Source:
NDA208114
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(2015)
Source:
NDA205739
(2015)
Source URL:
First approved in 2015
Source:
NDA205739
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(2015)
Source:
NDA205739
(2015)
Source URL:
First approved in 2015
Source:
NDA205739
Source URL:
Class:
POLYMER
